Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2025 10:04 ET | Source: Transparency Market Research

Global Amyloidosis Therapeutics Market Outlook to Exceed US$ 6.3 Billion by 2035 at 8.2% CAGR, Driven by Rising Disease Prevalence and Robust R&D Investments | Exclusive Report by TMR

Wilmington, Delaware, United States, Transparency Market Research Inc. – , Feb. 24, 2025 (GLOBE NEWSWIRE) -- The global amyloidosis therapeutics market, valued at US$ 2.7 Billion in 2024, is poised...
February 10, 2025 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Immunomodulator Clears Senescence

BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation...
January 06, 2025 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Immunomodulator Improves Fatty Liver Disease

BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation...
December 16, 2024 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor

BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
December 11, 2024 07:01 ET | Source: GEn1E Lifesciences Inc.

GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors

Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
November 07, 2024 10:43 ET | Source: Research and Markets

Immunomodulators Global Business Analysis Report 2024-2030: Growing Focus on Combination Therapies Enhances Market Opportunities, Increased Focus on Developing Targeted Therapies

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Immunomodulators - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immunomodulators...
October 14, 2024 06:02 ET | Source: GEn1E Lifesciences Inc.

GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies

GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
June 27, 2024 09:43 ET | Source: Research and Markets

Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications

Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Immunomodulator Market" report has been added to ResearchAndMarkets.com's offering.In a significant development for the healthcare industry,...
June 07, 2024 20:18 ET | Source: Qu Biologics, Inc.

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
July 07, 2011 10:33 ET | Source: Immune Network Ltd

Herbal TB Immunotherapy to be Presented at Hong Kong Conference

VANCOUVER, British Columbia, July 7, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical results from its new tableted form of Immunoxel (Dzherelo) product...

Next Page keyboard_arrow_right